CASIRAGHI, VALERIA
CASIRAGHI, VALERIA
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale
Modeling of TDP-43 proteinopathy by chronic oxidative stress identifies rapamycin as beneficial in ALS patient-derived 2D and 3D iPSC models
2025 V. Casiraghi, M.N. Sorce, S. Santangelo, S. Invernizzi, P. Bossolasco, C. Lattuada, C. Battaglia, M. Venturin, V. Silani, C. Colombrita, A. Ratti
AGGREGATION MECHANISMS OF TDP-43 PROTEIN IN RESPONSE TO STRESS IN AMYOTROPHIC LATERAL SCLEROSIS AND THERAPEUTIC APPROACHES
2024 V. Casiraghi
Quantification of serum TDP-43 and neurofilament light chain in patients with amyotrophic lateral sclerosis stratified by UNC13A genotype
2024 V. Casiraghi, I. Milone, A. Brusati, S. Peverelli, A. Doretti, B. Poletti, L. Maderna, C. Morelli, N. Ticozzi, V. Silani, F. Verde, A. Ratti
Rapamycin reverts TDP-43 splicing defects and mislocalization in human in vitro models of TDP-43 proteinopathy
2023 V. Casiraghi, C. Colombrita, S. Santangelo, S. Invernizzi, M.N. Sorce, P. Bossolasco, V. Silani, A. Ratti
U1 snRNA as a novel RNA-based therapeutic approach to modulate C9ORF72 pathology in patient-derived iPSC-motoneurons
2023 S. Invernizzi, S. Santangelo, E. Bussani, G. Romano, C. Colombrita, V. Casiraghi, M. Nice Sorce, P. Bossolasco, V. Silani, F. Pagani, A. Ratti
Exploring epigenetic drift and rare epivariations in amyotrophic lateral sclerosis by epigenome-wide association study
2023 A. Brusati, S. Peverelli, L. Calzari, C. Tiloca, V. Casiraghi, M.N. Sorce, S. Invernizzi, E. Carbone, R. Cavagnola, F. Verde, V. Silani, N. Ticozzi, A. Ratti, D. Gentilini
Association of the risk factor UNC13A with survival and upper motor neuron involvement in amyotrophic lateral sclerosis
2023 A. Manini, V. Casiraghi, A. Brusati, A. Maranzano, F. Gentile, E. Colombo, R. Bonetti, S. Peverelli, S. Invernizzi, D. Gentilini, S. Messina, F. Verde, B. Poletti, I. Fogh, C. Morelli, V. Silani, A. Ratti, N. Ticozzi
Rapamycin reverts TDP-43 splicing defects and mislocalization in human in vitro models of TDP-43 proteinopathy
2022 V. Casiraghi, C. Colombrita, S. Santangelo, I. Milone, M.N. Sorce, V. Silani, A. Ratti
Rapamycin reverts TDP-43 splicing defects and mislocalization in human in vitro models of TDP-43 proteinopathy
2022 V. Casiraghi, C. Colombrita, S. Santangelo, I. Milone, M.N. Sorce, V. Silani, A. Ratti
Rapamycin reverts TDP-43 splicing defects and oxidative stress-induced alterations in a human in vitro model of TDP-43 proteinopathy
2022 V. Casiraghi, C. Colombrita, S. Santangelo, I. Milone, M.N. Sorce, V. Silani, A. Ratti
Human in vitro models of TDP-43 proteinopathy for drug screening approaches
2022 V. Casiraghi, C. Colombrita, S. Santangelo, S. Invernizzi, M.N. Sorce, V. Silani, A. Ratti
Modelling ALS disease by 2D and 3D in vitro models of patient-derived iPSC
2022 P. Bossolasco, S. Santangelo, L. Lattuada, M.N. Sorce, C. Colombrita, V. Casiraghi, S. Peverelli, A. Ratti, V. Silani
U1 snRNA as a novel RNA-based therapeutic approach to modulate C9ORF72 pathology in patient-derived iPSC-motoneurons
2022 S. Santangelo, C. Colombrita, E. Bussani, S. Invernizzi, M. Nice Sorce, V. Casiraghi, C. Lattuada, P. Bossolasco, V. Silani, F. Pagani, A. Ratti